Shares of Cutera, Inc. (NASDAQ:CUTR) have received an average recommendation of “Buy” from the seven analysts that are covering the company, Marketbeat.com reports. Two equities research analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $39.50.

CUTR has been the subject of a number of analyst reports. Roth Capital lifted their price objective on Cutera from $41.00 to $47.00 and gave the stock a “buy” rating in a research note on Tuesday, September 12th. BidaskClub cut Cutera from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, July 19th. Gabelli reaffirmed a “buy” rating on shares of Cutera in a research note on Wednesday, August 9th. Maxim Group reaffirmed a “buy” rating and set a $33.00 price objective (up from $27.00) on shares of Cutera in a research note on Thursday, July 13th. Finally, TheStreet raised Cutera from a “c” rating to a “b” rating in a research note on Friday, August 18th.

In other Cutera news, CFO Ronald J. Santilli sold 5,775 shares of Cutera stock in a transaction dated Monday, September 11th. The stock was sold at an average price of $40.43, for a total transaction of $233,483.25. Following the transaction, the chief financial officer now directly owns 50,012 shares in the company, valued at $2,021,985.16. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CFO Ronald J. Santilli sold 12,000 shares of Cutera stock in a transaction dated Wednesday, August 16th. The stock was sold at an average price of $34.00, for a total value of $408,000.00. Following the transaction, the chief financial officer now owns 75,253 shares in the company, valued at $2,558,602. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 61,809 shares of company stock worth $2,182,510. Corporate insiders own 11.60% of the company’s stock.

Hedge funds have recently bought and sold shares of the business. American International Group Inc. lifted its holdings in Cutera by 7.0% during the first quarter. American International Group Inc. now owns 7,221 shares of the medical device company’s stock worth $149,000 after acquiring an additional 475 shares in the last quarter. Nationwide Fund Advisors lifted its holdings in Cutera by 8.4% during the second quarter. Nationwide Fund Advisors now owns 7,216 shares of the medical device company’s stock worth $187,000 after acquiring an additional 561 shares in the last quarter. Metropolitan Life Insurance Co. NY bought a new position in Cutera during the first quarter worth about $202,000. Cubist Systematic Strategies LLC bought a new position in Cutera during the second quarter worth about $225,000. Finally, PNC Financial Services Group Inc. bought a new position in Cutera during the second quarter worth about $241,000. Hedge funds and other institutional investors own 89.15% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This report was reported by Watch List News and is the property of of Watch List News. If you are reading this report on another website, it was illegally stolen and republished in violation of U.S. & international copyright law. The correct version of this report can be read at https://www.watchlistnews.com/cutera-inc-cutr-receives-average-rating-of-buy-from-analysts/1642235.html.

Shares of Cutera (NASDAQ CUTR) opened at 37.60 on Friday. The stock’s 50 day moving average price is $40.46 and its 200 day moving average price is $28.85. Cutera has a one year low of $12.45 and a one year high of $44.40. The stock has a market capitalization of $526.59 million, a P/E ratio of 80.86 and a beta of 0.53.

Cutera (NASDAQ:CUTR) last announced its quarterly earnings data on Monday, August 7th. The medical device company reported $0.13 EPS for the quarter, topping analysts’ consensus estimates of $0.03 by $0.10. Cutera had a return on equity of 11.64% and a net margin of 5.07%. The business had revenue of $36.40 million during the quarter, compared to analysts’ expectations of $32.08 million. During the same period in the previous year, the firm earned $0.07 earnings per share. The firm’s quarterly revenue was up 32.4% compared to the same quarter last year. On average, analysts forecast that Cutera will post $0.52 EPS for the current year.

Cutera declared that its board has authorized a stock buyback program on Monday, August 7th that allows the company to buyback $25.00 million in outstanding shares. This buyback authorization allows the medical device company to purchase up to 6.8% of its stock through open market purchases. Stock buyback programs are typically an indication that the company’s management believes its stock is undervalued.

About Cutera

Cutera, Inc is a medical device company. The Company is engaged in the design, development, manufacture, marketing and servicing of laser and other energy-based aesthetics systems for practitioners across the world. The Company offers products based on product platforms, such as enlighten, excel HR, truSculpt, excel V and xeo, each of which enables physicians and other practitioners to perform aesthetic procedures for customers.

Receive News & Ratings for Cutera Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cutera Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.